Improved process for preparation of ruxolitinib

By employing a novel synthetic route and purification method, the problems of low yield and purity of ruxolitinib in existing technologies have been solved, enabling efficient and low-cost industrial preparation of ruxolitinib.

CN119032095APending Publication Date: 2024-11-26GRANULES INDIA LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033279.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-08-22
Filing Date
2023-08-21
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing technologies for preparing ruxolitinib suffer from low yield, low purity, and the use of expensive chiral reagents and complex chiral resolution reactions, making them unsuitable for industrial production.

Method used

A novel synthetic route was adopted, including the reaction, amination, and deprotection steps of the compound, and purification was carried out using dicyclohexylamine salt, which simplified the preparation process and improved the yield and purity of ruxolitinib.

Benefits of technology

This method achieves high yield and high purity preparation of ruxolitinib, simplifies the process, reduces production costs, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032095A_ABST
    Figure CN119032095A_ABST
Patent Text Reader

Abstract

The main purpose of the present invention is to improve the preparation method of ruxolitinib, which uses protected (E)-N-(3-(dimethylamino)-2-(7H-pyrrolo [2, 3-d] pyrimidine-4-yl) allylidene)-N-methyl ammonium chloride hydrochloride and (R)-5-cyclopentylpyrazolidine-3-one D-tartrate, the process produces at a higher yield on an industrial scale. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to an improved method for preparing ruxolitinib or a pharmaceutically acceptable salt thereof, and a method for preparing related intermediates. Background Art

[0002] Ruxolitinib is a selective JAK1 / JAK2 tyrosine kinase inhibitor developed by Incyte and Novartis. It is the first drug approved by the US FDA in November 2011 to treat myelofibrosis (trade name: Jakafi), and its indications are moderate or high-risk myelofibrosis, including primary myelofibrosis, secondary polycythemia myelofibrosis, and post-essential thrombocythemia myelofibrosis.

[0003] Ruxolitinib phosphate is chemically known as (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropionitrile phosphate and has the following structural formula:

[0004]

[0005] U.S. Patent No. 7,598,257 discloses ruxolitinib and its pharmaceutically acceptable salts. In addition, it discloses a method for preparing ruxolitinib, which includes separating intermediates using an HPLC method and purifying the final product using a column chromatography purification method, which is laborious and time-consuming, with low yield and low purity.

[0006] U.S. Patent No. 8,410,265 discloses a method for preparing ruxolitinib, which involves chemical splitting of D-(+)-dibenzoyltartaric acid, asymmetric hydrogenation under the action of a chiral metal catalyst, and an asymmetric synthesis route of ruxolitinib catalyzed by a chiral small molecule. Chemical splitting and repeated recrystallization are performed, and the yield is low; the starting material for asymmetric hydrogenation is not easy to prepare, and the preparation of the chiral catalyst is difficult; the chiral small molecule catalyst is a non-commercial product, the preparation cost is high, and the stereoselectivity of the reaction is not high.

[0007] The above prior art methods involve chiral resolution reactions at the final stage (which result in yield loss), chromatographic purification methods and the use of expensive chiral and hazardous reagents. The use of complex chiral reagents increases production costs. The use of chromatographic purification methods is not suitable for industrial production.

[0008] In view of the above, there is still a great need to develop an improved process for preparing high-purity ruxolitinib suitable for industrial production. The inventors of the present invention focus more on solving the shortcomings of the prior art methods and have developed a new method for preparing ruxolitinib, which is more suitable for industrial production. Summary of the invention

[0009] In one aspect, the present invention provides a method for preparing ruxolitinib or a salt thereof, the method comprising:

[0010] The compound of formula 4 or a salt thereof,

[0011]

[0012] Reaction with a compound of formula 5,

[0013]

[0014] Wherein, 'P' represents hydrogen or an amine protecting group, X - It is the counterbalancing anion.

[0015] In another aspect, the present invention provides a method for preparing ruxolitinib or a salt thereof, the method comprising:

[0016] A) making a compound of formula 4 or a salt thereof,

[0017]

[0018] Reaction with a compound of formula 5,

[0019]

[0020] Wherein, 'P' represents hydrogen or an amine protecting group, X - It is the counter-anion;

[0021] To provide an acid compound of formula 6;

[0022]

[0023] B) reacting the acid compound of formula 6 with an alkyl chloroformate, a dialkyl dicarbonate, an alkyl or aryl sulfonyl chloride, or a sulfonic anhydride to provide a compound of formula 7a;

[0024]

[0025] Wherein 'Y' represents COOR, SO2R, and R is selected from alkyl, aryl or aralkyl;

[0026] C) reacting a compound of formula 7a with an aminating agent to provide a compound of formula 8; and

[0027]

[0028] D) converting the compound of formula 8 into ruxolitinib or a salt thereof.

[0029] In another aspect, the present invention provides a method for purifying a compound of formula 6, the method comprising:

[0030]

[0031] wherein 'P' represents hydrogen or an amine protecting group;

[0032] The compound of formula 6 is reacted with a dicyclohexylamine (DCHA) salt in a suitable solvent to provide a dicyclohexylamine salt of the compound of formula 6a, and

[0033]

[0034] The compound of Formula 6a can be further converted to a free base by reacting its dicyclohexylamine salt with a base to provide a pure compound of Formula 6.

[0035] In another aspect, the present invention provides the use of a dicyclohexylamine salt of a compound of formula 6a or a pure compound of formula 6 in the preparation of ruxolitinib or a salt thereof,

[0036]

[0037] Wherein, 'P' represents hydrogen or an amine protecting group.

[0038] In another aspect, the present invention provides a method for preparing ruxolitinib or a salt thereof, the method comprising:

[0039] A) making an acid intermediate of formula 6,

[0040]

[0041] wherein 'P' represents hydrogen or an amine protecting group;

[0042] reacting with an alkyl chloroformate, a dialkyl dicarbonate, an alkyl or aryl sulfonyl chloride, or a sulfonic anhydride to provide a compound of formula 7a;

[0043]

[0044] Wherein 'Y' represents COOR, SO2R, and R is selected from alkyl, aryl or aralkyl;

[0045] B) reacting a compound of formula 7a with an aminating agent to provide a compound of formula 8; and

[0046]

[0047] B) converting the compound of formula 8 into ruxolitinib or a salt thereof. DETAILED DESCRIPTION

[0048] The "suitable solvent" used in the present invention can be selected from but not limited to: "hydrocarbon solvents", such as n-pentane, n-hexane, n-heptane, cyclohexane, petroleum ether, benzene, toluene, xylene, etc.; "ether solvents", such as dimethyl ether, diethyl ether, diisopropyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, tetrahydrofuran, 1,4-dioxane, etc.; "ester solvents", such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, tert-butyl acetate, etc.; "polar aprotic solvents", such as dimethylacetamide, dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone, etc.; "chlorinated solvents" such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.; "ketone solvents" such as acetone, methyl ethyl ketone, methyl isobutyl ketone, etc.; "nitrile solvents" such as acetonitrile, propionitrile, isobutyronitrile, etc.; "alcohol solvents" such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, 2-butanol, tert-butanol, ethane-1,2-diol, propane-1,2-diol, etc.; "polar solvents" such as formic acid, acetic acid, etc.; and water or any mixture of the above solvents.

[0049] Suitable "amine protecting groups 'P'" may be selected from, but are not limited to, benzyloxycarbonyl (Cbz), 2,2,2-trichloroethoxycarbonyl (Troc), 2-(trimethylsilyl)ethoxycarbonyl (Teoc), 2-(4-trifluoromethylphenylsulfonyl)ethoxycarbonyl (Tsc), tert-butoxycarbonyl (Boc), 1-adamantyloxycarbonyl (Adoc), 2-adamantylcarbonyl (2-Adoc), 2,4-dimethylpentyl-3-oxycarbonyl (Doc), cyclohexyloxycarbonyl (Hoc), 1,1-dimethyl-2,2,2-trichloroethoxycarbonyl (TcBoc), vinyl, 2-chloro Ethyl, 2-phenylsulfonylethyl, p-nitrobenzenesulfonyl, p-toluenesulfonyl, benzyl, methanesulfonyl, allyl, benzyl, 2-nitrobenzyl, 4-nitrobenzyl, diphenyl-4-pyridylmethyl, N',N'-dimethylhydrazine, methoxymethyl, tert-butoxymethyl (Bum), benzyloxymethyl (Bom), 2-tetrahydropyranyl (THP), tri(C1-4alkyl)silyl, 1,1-diethoxymethyl, 2-(trimethylsilyl)ethoxymethyl (SEM), N-pivaloyloxymethyl (N-pivaloyloxymethyl) (POM), etc.

[0050] "Suitable deprotecting agent" is selected based on the protecting group used. Suitable deprotecting agents can be selected from, but are not limited to: acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, aq. phosphoric acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, trifluoroacetic anhydride, lithium tetrafluoroborate, boron trifluoride-ethyl ether; combinations of acetyl chloride and alcohols; bases such as alkali metal hydroxides, alkali metal carbonates, cesium carbonate / imidazole, alkali metal bicarbonates, ammonia, aqueous ammonia, cerium (IV) ammonium nitrate (CAN); and organic bases such as methylamine, ethylamine, diethylamine, triethylamine, piperidine; hydrogenating agents such as Pd / C, Pd(OH)2 / C (Pearlman catalyst), palladium acetate, platinum oxide, platinum black, sodium borohydride, Na-liquid ammonia, Raney Ni, Zn-acetic acid, tri(C1-C6)alkylsilane, tri(C1-C6)alkylsilyl halide, and the like.

[0051] According to one embodiment, the present invention provides a method for preparing ruxolitinib or a salt thereof, the method comprising:

[0052] The compound of formula 4 or a salt thereof,

[0053]

[0054] Reaction with a compound of formula 5,

[0055]

[0056] Wherein, 'P' represents hydrogen or an amine protecting group, X - It is the counterbalancing anion.

[0057] In the above method, the compound of formula 4 can be a free base or a salt thereof, and the salt of formula 4 can be a chiral salt or an achiral salt.

[0058] In the present invention, the chiral acid used to form the chiral salt can be selected from the following acids or their enantiomeric excess forms: mandelic acid, 2-chloromandelic acid, camphoric acid, lactic acid, malic acid, 3-bromocamphor-8-sulfonic acid, 3-bromocamphor-10-sulfonic acid, 10-camphorsulfonic acid, 2-amino-7,7-dimethylbicyclo[2,2,1]heptane-1-methylenesulfonic acid, 2-acrylamide-7,7-dimethylbicyclo[2,2,1]heptane-1-methylenesulfonic acid, or tartaric acid and its acyl derivatives, preferably Select lactic acid, malic acid, camphoric acid, 10-camphorsulfonic acid, tartaric acid, diacetyl tartaric acid, dibenzoyl tartaric acid, two to toluoyl tartaric acid, two to anisyl tartaric acid, two to chlorobenzoyl tartaric acid, two to bromobenzoyl tartaric acid, two to fluorobenzoyl tartaric acid, two to nitrobenzoyl tartaric acid, two to aminobenzoyl tartaric acid or two to cyanobenzoyl tartaric acid etc.; preferably tartaric acid, diacetyl tartaric acid, dibenzoyl tartaric acid or two to toluoyl tartaric acid.

[0059] In the present invention, the chiral acid used to form the chiral salt can be selected from: D-tartaric acid, D-diacetyltartaric acid, D-dibenzoyltartaric acid, D-di-p-toluoyltartaric acid, D-di-p-anisyltartaric acid, D-di-p-chlorobenzoyltartaric acid, D-di-p-bromobenzoyltartaric acid, D-di-p-fluorobenzoyltartaric acid, D-di-p-nitrobenzoyltartaric acid, D-di-p-aminobenzoyltartaric acid, D-di-p-cyanobenzoyltartaric acid, etc.; preferably D-tartaric acid, D-dibenzoyltartaric acid or D-di-p-toluoyltartaric acid; more preferably D-tartaric acid.

[0060] In the present invention, the achiral salt is selected from: hydrochloride, hydrobromide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, fumarate, oxalate, maleate, citrate, succinate, methanesulfonate, benzenesulfonate and p-toluenesulfonate, preferably hydrochloride, hydrobromide, sulfate, formate, acetate, trifluoroacetate, fumarate, maleate, methanesulfonate or p-toluenesulfonate, etc.; preferably hydrochloride or acetate.

[0061] In the above method, X - is a counter anion, the counter anion is selected from but not limited to Cl - Br - ,I - OMs - ,OTf - 、B4 - PF6 - 、AsF6 - 、SbF6 - 、ClO4 - etc.; preferably Cl - .

[0062] The above method can be carried out in the presence of a suitable solvent; preferably a polar aprotic solvent, a nitrile solvent, an alcohol solvent, water or a mixture thereof; more preferably dimethylformamide, acetonitrile, ethanol, water or a mixture thereof.

[0063] In another embodiment, the present invention provides a method for preparing ruxolitinib or a salt thereof, the method comprising:

[0064] A) making a compound of formula 4 or a salt thereof,

[0065]

[0066] Reaction with a compound of formula 5,

[0067]

[0068] Wherein, 'P' represents hydrogen or an amine protecting group, X - It is the counter-anion;

[0069] To provide an acid intermediate of formula 6;

[0070]

[0071] B) reacting the acid intermediate of formula 6 with an alkyl chloroformate, a dialkyl dicarbonate, an alkyl or aryl sulfonyl chloride, or a sulfonic anhydride to provide a compound of formula 7a;

[0072]

[0073] Wherein 'Y' represents COOR, SO2R, and R is selected from alkyl, aryl or aralkyl;

[0074] C) reacting a compound of formula 7a with an aminating agent to provide a compound of formula 8; and

[0075]

[0076] E) converting the compound of formula 8 into ruxolitinib or a salt thereof.

[0077] In step A) of the above method, the compound of formula 4 used may be a free base or a salt thereof, and the salt of formula 4 may be a chiral salt or an achiral salt.

[0078] In the present invention, the chiral acid used to form the chiral salt can be selected from the following acids or their enantiomeric excess forms: mandelic acid, 2-chloromandelic acid, camphoric acid, lactic acid, malic acid, 3-bromocamphor-8-sulfonic acid, 3-bromocamphor-10-sulfonic acid, 10-camphorsulfonic acid, 2-amino-7,7-dimethylbicyclo[2,2,1]heptane-1-methylenesulfonic acid, 2-acrylamide-7,7-dimethylbicyclo[2,2,1]heptane-1-methylenesulfonic acid, or tartaric acid and its acyl derivatives, preferably Select lactic acid, malic acid, camphoric acid, 10-camphorsulfonic acid, tartaric acid, diacetyl tartaric acid, dibenzoyl tartaric acid, two to toluoyl tartaric acid, two to anisyl tartaric acid, two to chlorobenzoyl tartaric acid, two to bromobenzoyl tartaric acid, two to fluorobenzoyl tartaric acid, two to nitrobenzoyl tartaric acid, two to aminobenzoyl tartaric acid or two to cyanobenzoyl tartaric acid etc.; preferably tartaric acid, diacetyl tartaric acid, dibenzoyl tartaric acid or two to toluoyl tartaric acid.

[0079] In the present invention, the chiral acid used to form the chiral salt can be selected from: D-tartaric acid, D-diacetyltartaric acid, D-dibenzoyltartaric acid, D-di-p-toluoyltartaric acid, D-di-p-anisyltartaric acid, D-di-p-chlorobenzoyltartaric acid, D-di-p-bromobenzoyltartaric acid, D-di-p-fluorobenzoyltartaric acid, D-di-p-nitrobenzoyltartaric acid, D-di-p-aminobenzoyltartaric acid, D-di-p-cyanobenzoyltartaric acid, etc.; preferably D-tartaric acid, D-dibenzoyltartaric acid or D-di-p-toluoyltartaric acid; more preferably D-tartaric acid.

[0080] In the present invention, the achiral salt is selected from: hydrochloride, hydrobromide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, fumarate, oxalate, maleate, citrate, succinate, methanesulfonate, benzenesulfonate and p-toluenesulfonate, preferably hydrochloride, hydrobromide, sulfate, formate, acetate, trifluoroacetate, fumarate, maleate, methanesulfonate or p-toluenesulfonate, etc.; preferably hydrochloride or acetate.

[0081] In step A) of the above method, X - is a counter anion, the counter anion is selected from but not limited to Cl - Br - ,I - OMs - ,OTf - 、BF4 - PF6 - 、AsF6 - 、SbF6 - 、ClO4 - etc.; preferably Cl - .

[0082] The reaction in step A) of the above method can be carried out in the presence of a suitable solvent; preferably a polar aprotic solvent, a nitrile solvent, an alcohol solvent, water or a mixture thereof; more preferably dimethylformamide, acetonitrile, ethanol aqueous solution or a mixture thereof.

[0083] In step B) of the above method, the alkyl chloroformate, dialkyl dicarbonate, alkyl or aryl sulfonyl chloride, and sulfonic anhydride used are selected from: ethyl chloroformate, methyl chloroformate, isobutyl chloroformate, dimethyl dicarbonate, diethyl dicarbonate, di-tert-butyl dicarbonate, methanesulfonyl chloride, ethanesulfonyl chloride, toluenesulfonyl chloride, methanesulfonic anhydride, toluenesulfonic anhydride, etc.; preferably ethyl chloroformate or methanesulfonyl chloride; more preferably ethyl chloroformate.

[0084] The step B) reaction of the above method can be carried out in the presence of a base in a suitable solvent; wherein the base is selected from triethylamine, methylamine, ethylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); preferably triethylamine, and the suitable solvent is selected from chlorinated solvents such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc., or a mixture thereof; preferably dichloromethane.

[0085] The intermediate compound of formula 7a obtained in step B) of the present invention can be continued in situ or alternatively isolated.

[0086] In step C) of the above method, the aminating agent used is selected from aqueous ammonia, liquid ammonia, ammonia gas, etc.; aqueous ammonia is preferred.

[0087] In step C) of the above process, the reaction can be carried out in the presence or absence of a suitable solvent.

[0088] In step D) of the above method, the conversion of the compound of formula 8 into ruxolitinib or a salt thereof can be carried out in the presence of a suitable dehydrating agent in a suitable solvent.

[0089] Suitable dehydrating agents are selected from: phosphorus oxychloride, cyanuric chloride, phosphorus pentoxide, thionyl chloride, trifluoroacetic anhydride, trifluorosulfonic anhydride, oxalyl chloride, etc.; preferably phosphorus oxychloride, trifluoroacetic anhydride or cyanuric chloride; more preferably phosphorus oxychloride.

[0090] Suitable solvents are selected from: chlorinated solvents such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc., polar aprotic solvents such as dimethylacetamide, dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone, etc., or mixtures thereof; preferably dichloromethane or N-methylpyrrolidone or mixtures thereof.

[0091] In step A) to step D) of the above-mentioned method, removal of the protecting group (when "P" is an amine protecting group) at any stage can be carried out in the presence of a suitable deprotecting agent.

[0092] The deprotecting agent used under acidic conditions is selected from trifluoroacetic acid, trifluoroacetic anhydride, lithium tetrafluoroborate, boron trifluoride-ethyl ether, etc., preferably trifluoroacetic acid or boron trifluoride-ethyl ether.

[0093] The deprotecting agent used under alkaline conditions is selected from aqueous solutions or alcohol solutions of alkali metal hydroxides or alkaline earth metal hydroxides, such as sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, barium hydroxide, calcium hydroxide, beryllium hydroxide, strontium hydroxide, radium hydroxide, etc., preferably sodium hydroxide aqueous solution or sodium hydroxide methanol solution.

[0094] In another embodiment, the present invention provides a method for purifying a compound of formula 6, the method comprising:

[0095]

[0096] wherein 'P' represents hydrogen or an amine protecting group;

[0097] The compound of formula 6 is reacted with a dicyclohexylamine (DCHA) salt in a suitable solvent to provide a dicyclohexylamine salt of the compound of formula 6a, and

[0098]

[0099] The compound of Formula 6a can be further converted to a free base by reacting its dicyclohexylamine salt with a base to provide a pure compound of Formula 6.

[0100] In the above method, the base used is selected from alkali metal hydroxides or alkaline earth metal hydroxides, such as sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, barium hydroxide, calcium hydroxide, beryllium hydroxide, strontium hydroxide, radium hydroxide, etc.; preferably sodium hydroxide; the suitable solvent used is selected from ketone solvents, such as acetone, methyl isobutyl ketone, methyl ethyl ketone, etc.; preferably acetone.

[0101] In another embodiment, the present invention provides the use of a dicyclohexylamine salt of a compound of formula 6a or a pure compound of formula 6 in the preparation of ruxolitinib or a salt thereof,

[0102]

[0103] Wherein, 'P' represents hydrogen or an amine protecting group.

[0104] In another embodiment, the present invention provides a method for preparing ruxolitinib or a salt thereof, the method comprising:

[0105] A) making an acid intermediate of formula 6,

[0106]

[0107] wherein 'P' represents hydrogen or an amine protecting group;

[0108] reacting with an alkyl chloroformate, a dialkyl dicarbonate, an alkyl or aryl sulfonyl chloride, or a sulfonic anhydride to provide a compound of formula 7a;

[0109]

[0110] Wherein 'Y' represents COOR, SO2R, and R is selected from alkyl, aryl or aralkyl;

[0111] B) reacting a compound of formula 7a with an aminating agent to provide a compound of formula 8; and

[0112]

[0113] C) converting the compound of formula 8 into ruxolitinib or a salt thereof.

[0114] In another embodiment, the present invention provides a method for preparing ruxolitinib or a salt thereof, the method comprising:

[0115] A) making an acid intermediate of formula 6,

[0116]

[0117] wherein 'P' represents hydrogen or an amine protecting group;

[0118] reacting with a coupling agent and then reacting with an aminating agent to provide a compound of formula 8; and

[0119]

[0120] B) converting the compound of formula 8 into ruxolitinib or a salt thereof.

[0121] In the above method, the coupling agent used is selected from: 1,1'-carbonyldiimidazole (CDI), 1,1'-thiocarbonyldiimidazole, 1,3-dicyclohexylcarbodiimide, 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride, etc.; preferably carbonyldiimidazole; the aminating agent used is selected from ammonia water, liquid ammonia, ammonia gas, etc.; preferably ammonia water.

[0122] In another embodiment, the present invention provides a method for preparing ruxolitinib or a salt thereof, the method comprising:

[0123] A) making a compound of formula 4 or a salt thereof,

[0124]

[0125] Reaction with a compound of formula 9,

[0126]

[0127] To provide a compound of formula 10;

[0128]

[0129] B) converting the compound of formula 10 into the corresponding ester compound of formula 11;

[0130]

[0131] wherein 'R' represents a C1-C4 alkyl group;

[0132] C) reacting a compound of formula 11 with a suitable halogenating agent to provide a compound of formula 12;

[0133]

[0134] wherein 'R' is as defined above;

[0135] D) reacting a compound of formula 12 with a compound of formula 13,

[0136]

[0137] Among them, 'X I ' represents a suitable leaving group;

[0138] To provide a compound of formula 14;

[0139]

[0140] wherein 'R' is as defined above;

[0141] E) reacting a compound of formula 14 with an aminating agent to provide a compound of formula 8; and

[0142]

[0143] F) converting the compound of formula 8 into ruxolitinib or a salt thereof.

[0144] The following examples are provided as further detailed non-limiting descriptions of the technical solutions of the present application. They should not be interpreted as limiting the scope of the present application, but only as descriptions and typical representatives of the present application.

[0145] Examples

[0146] Example 1:

[0147] Step 1: Preparation of 3-cyclopentylacrylic acid:

[0148]

[0149] THF (2 vols) and DMF (1.2 vols) were added to RBF and cooled to 0-5°C, cyclopentylmagnesium bromide - 2.0 M in ether (50.0 g, 1.0 eq) was added and the temperature was raised to room temperature. The reaction mass was stirred at room temperature for 30-45 minutes (the progress of the reaction was monitored by TLC). After the completion of the reaction, the reaction was quenched by adding water (0.3 vol) to the mass. The reaction mass was filtered and the filtrate was added to RB flask and pyridine (1.9 vols), piperidine (0.01 vol) and malonic acid (0.68 eq) were added to RBF at room temperature and stirred for 5-10 minutes (observation: the reaction mass was heterogeneous). The reaction mixture was heated to reflux and stirred at reflux for 7-8 hours. After the completion of the reaction, the reaction mass was cooled to 0-5°C and the pH of the reaction mass was adjusted to 1-2 at 0-5°C by adding 3N HCl aqueous solution (~5.0 vols). The mass was extracted twice with ethyl acetate (2×5 vols). The pH of the organic layer was adjusted to 11-12 by adding 2M aqueous NaOH solution (-20 volumes) at 0-5° C. The layers were separated, the aqueous layer was washed with ethyl acetate (2×5 volumes), and the pH of the aqueous layer was adjusted to 1-2 with concentrated HCl (-3 volumes) at 0-5° C. Then, the compound was extracted from the aqueous layer with ethyl acetate (2×7.5 volumes), the organic layer was washed with 5% aqueous NaCl solution (2.5 volumes), and the solvent was distilled off under reduced pressure to obtain the title compound.

[0150] Yield: ~20g

[0151] Step 2: Preparation of 5-cyclopentylpyrazolidin-3-one:

[0152]

[0153] 3-Cyclopentylacrylic acid (75.0 g, 1.0 equiv) and hydrazine hydrate (75%, 1 volume) were added at room temperature. The reaction mixture was heated to 70-75°C and stirred at 70-75°C for 30-45 minutes. After completion of the reaction, the reaction mass was concentrated to minimum volume at 70°C under reduced pressure and then water (1 volume) was added to the reaction mixture. The reaction mass was cooled to 0-5°C and stirred for 12 hours. The solid was filtered and washed with MTBE (0.5 volume, 37.5 mL) to get wet material (~25 gm). The compound was dried at 45°C to get 5-cyclopentylpyrazolidin-3-one (~18 g, 1 st Yield). The filtrate mL was extracted with DCM (~5 vol) and then the solvent was distilled off under reduced pressure to give the title compound (~17 gm, 2 nd Yield).

[0154] Total weight = ~35gm (1 st +2nd Yield).

[0155] Step 3: Preparation of (R)-5-cyclopentylpyrazolidin-3-one D-tartrate:

[0156]

[0157] 5-Cyclopentylpyrazolidin-3-one (35.0 g, 1.0 equiv) and acetone (10.0 vol) were added to RBF and the mixture was stirred at room temperature for 10-15 min (Observation: reaction mass was homogeneous). D-(-)-Tartaric acid (0.50 equiv) was added to the reaction mixture and the heterogeneous mixture was stirred at room temperature for 30-45 min. The reaction mixture was cooled to 0-5°C and stirred at the same temperature for 1 hour. The solid was filtered and washed with pre-cooled acetone (1.0 vol) to obtain wet material. The compound was dried under vacuum at 45-50°C to obtain the title compound.

[0158] Yield: ~30g

[0159] Example 2:

[0160] Step 1: Preparation of 4-methyl-7H-pyrrolo[2,3-d]pyrimidine:

[0161]

[0162] 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine 4-methyl-7H-pyrrolo[2,3-d]pyrimidine

[0163] 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (SM, 25.0 g, 1.0 eq.) and Pd(dppf)Cl2.DCM (0.0071 eq.) along with THF (5 vol.) were added to RBF at room temperature and stirred at the same temperature for 30-45 min. The mass was cooled to 0-5°C and MeMgBr (3.0 M, ether solution, 2.8 eq.) was added to the reaction mass. The reaction mass was heated to 55-65°C and stirred at the same temperature for 6-7 hours (reaction progress was monitored by TLC). After completion of the reaction, the reaction mass was cooled to 0-5°C and quenched with concentrated hydrochloric acid (~3 vol.) at 0-5°C. Water (~4 vol.) was added to the reaction mixture and the layers were separated. The pH of the aqueous layer was adjusted to ~7 by adding NaHCO3 aqueous solution (4 vol.) and extracted with ethyl acetate (3×6 vol.). The organic layer was treated with activated carbon (5.0%, 0.05w / w, 1.25g), and the solvent was distilled off from the filtrate under reduced pressure to obtain a crude compound. The crude compound was further purified by silica gel column to obtain the title compound.

[0164] Yield: ~10 g

[0165] Step 2: Preparation of (E)-N-(3-(dimethylamino)-2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)allylidene)-N-methylmethanaminium chloride hydrochloride:

[0166]

[0167] Acetonitrile (6.5 volumes) and oxalyl chloride (2.0 equiv) were added to RBF at room temperature. The reaction mass was cooled to 0-5°C and DMF (7.5 volumes) was added. The temperature of the reaction mass was raised to room temperature and the compound of step 1 (13.0 g, 1.0 equiv) was added to the reaction mixture. The reaction mixture was heated to 80-85°C and stirred at 80-85°C for 6 hours. After the reaction was completed, THF (20 volumes) was added at 40-45°C and the reaction mass was kept at room temperature for 12 hours. The reaction mass was allowed to settle for 30-45 minutes, the upper THF layer was removed, and washed twice with MTBE (2×5 volumes), and the reaction mass was filtered under nitrogen / inert atmosphere (hygroscopic) to obtain the title compound.

[0168] Yield: ~5g

[0169] Example 3:

[0170] Preparation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanoic acid:

[0171]

[0172] (R)-5-Cyclopentylpyrazolidin-3-one D-tartrate (30.0 g, 1.0 eq), ethanol (6 vols) and water (3 vols) were added to RBF at room temperature. Then (E)-N-(3-(dimethylamino)-2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)allylidene)-N-methylmethanaminium chloride hydrochloride (1.1 eq) was added and the reaction mixture was heated at 70-75°C for 6-7 hours. After completion of the reaction, the solvent was distilled off under reduced pressure at a temperature below 50°C and then pH was adjusted to ~7-8 at room temperature by adding saturated aqueous NaHCO3 solution (20.0 vols). The reaction mass was washed with DCM (3 x 6 vols) and then pH of the aqueous layer was adjusted to ~1-2 by adding concentrated hydrochloric acid (3.0 vols) at 0-5°C. The compound was extracted with ethyl acetate (3 x 12 vols) and then the organic layer was distilled off under reduced pressure to obtain the title compound.

[0173] Yield: 13.0 g

[0174] Example 4:

[0175] Step 1: Preparation of 4-methyl-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid benzyl ester

[0176]

[0177] 4-Methyl-7H-pyrrolo[2,3-d]pyrimidine (100 g, 1.0 equiv.) and acetonitrile (3 V) were added to RBF at 25-35 °C under nitrogen atmosphere. Pyridine (5 V) was added to the material and stirred at the same temperature for 10-15 minutes. The reaction mass was cooled to 0 to -5 °C, benzyl chloroformate (2.0 equiv.) was added at less than 10 °C, the temperature was raised to 25 to 35 °C, and stirred at the same temperature for 6 to 8 hours. After the reaction was completed, the reaction mass was cooled to 0-10 °C, water (25 V) was added at 0 to -5 °C, and stirred at 0 to -5 °C for 1-2 hours. The solid obtained was filtered, washed with ACN aqueous solution (1:1 ratio, 2×2 V), and vacuum dried at 50 to 60 °C to obtain the title compound.

[0178] Yield: ~160g

[0179] Step 2: Preparation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanoic acid:

[0180]

[0181] Acetonitrile (6.5V) was added to RBF at 20-30°C under nitrogen atmosphere, and cooled to 0-10°C, oxalyl chloride (2.1 equivalents) was added, stirred for 10-20 minutes, and then DMF (15.0 equivalents) was slowly added and stirred at the same temperature for 1-2 hours. The temperature of the reaction mass was then raised to 20-30°C, 4-methyl-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid benzyl ester (90g) was added, and stirred at room temperature for 10-15 minutes. The temperature of the reaction mass was heated to 70-80°C again and stirred at the same temperature for 6-8 hours. After the reaction was completed, THF (20V) was added to the reaction mass and stirred overnight. The organic layer was decanted, the material was washed with MTBE (5×5V), and the compound was dried under vacuum to obtain Vilsmeier salt (91g). Ethanol (6.0 V) and water (3.0 V) were added to Vilsmeier salt at room temperature, stirred for 5-10 minutes and (R)-5-cyclopentylpyrazolidin-3-one D-tartrate (1.0 eq.) was added at the same temperature. The reaction mass was heated to 70-80°C, stirred at the same temperature for 6-8 hours and cooled to 20-30°C. The solvent was distilled off under vacuum, HCl aqueous solution (3.0 V) was added, heated to 70-80°C and stirred at the same temperature for 1-2 hours. The reaction mass was cooled to 0-5°C, the pH of the mass was adjusted to ~8 with NaHCO3 aqueous solution (20 V) and washed with ethyl acetate (12 V). The pH of the reaction mass was adjusted to ~3 by adding HCl aqueous solution (3.0 V) at 0-5°C. The compounds of the reaction mass were extracted with ethyl acetate (2×12 V) and the solvent was distilled off under reduced pressure to obtain the title compound.

[0182] Yield: 37 g

[0183] Step 3: Purification of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanoic acid:

[0184] Crude (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanoic acid (328.0 g, 1.0 eq.) and acetone (10 V) were added to RBF at room temperature. The reaction mass was heated to 40-50°C, activated carbon (0.05 T) was added, and maintained at the same temperature for 30-45 minutes. The reaction mass was filtered on a diatomaceous earth bed (0.2 T) and washed with acetone (1 V). The filtrate obtained was added to RBF, heated to 40-50°C, dicyclohexylamine (DCHA, 1.0-1.5 eq., until the pH of the mass was 9-9.5) was added, and maintained at 50-60°C for 1-2 hours. The reaction mass was then cooled to room temperature and stirred at the same temperature for 1-2 hours. The obtained solid was filtered and washed with acetone (1.0 V) to obtain the wet compound. The obtained wet compound (230 g) and acetone (5 V) were added to RBF at room temperature, heated to 50-60° C. and maintained at the same temperature for 1-2 hours. The reaction mass was cooled to room temperature and stirred at the same temperature for 1-2 hours. The obtained solid was filtered, washed with acetone (1 V), and dried in VTD for 6-8 hours (198.0 g) to obtain DCHA salt.

[0185] Water (5V) was added to the DCHA salt obtained above and the pH of the reaction mass was adjusted to 13-14.0 by adding aqueous sodium hydroxide solution. The aqueous layer was washed with MTBE (3×6V) and the pH of the aqueous layer was adjusted to 5.2 to 5.5 by adding aqueous HCl solution. The reaction mass was extracted with 10% methanol in ethyl acetate solution (4×5V) and the organic layer was washed with saturated aqueous NaCl solution (2V). Charcoal (0.1T) was added to the organic layer at 40-50°C and stirred for 1-2 hours, filtered on a celite bed and the filtrate was distilled off at a temperature below 55°C under reduced pressure until 4.0-5.0 volumes of n-heptane (5V) were added to the reaction mass at 40-50°C and the mass was gradually cooled to room temperature and stirred at the same temperature for 3-4 hours. The solid obtained was filtered, washed with n-heptane (1V) and dried at 50-55°C under VTD for 6-8 hours to obtain the pure title compound.

[0186] Yield: 103 g

[0187] Step 4: Preparation of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropionamide:

[0188]

[0189] (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanoic acid (crude product, 45.0 g, 1.0 eq.), DCM (10.0 V), TEA (1.3 eq.) were added in RBF at room temperature and cooled to -15 to -25 °C, then ethyl chloroformate (1.10 eq.) was added and maintained at the same temperature for 1-2 hours (reaction progress was monitored by TLC). After completion of the reaction, the reaction mass was quenched with ammonia in methanol solution (~10 V) and maintained at the same temperature for 1-2 hours. Then the temperature of the reaction mass was raised to room temperature, water (10 v) was added and stirred for 20-30 minutes. The layers were separated and the aqueous layer was extracted with DCM (4×10 V) at room temperature. The organic layers were combined and washed with saturated NaHCO3 solution (10 v) and the solvent was distilled off under reduced pressure to obtain the title compound.

[0190] Yield: 35g

[0191] Step 5: Preparation of ruxolitinib

[0192]

[0193] (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropionamide (5.0 g, 1.0 eq), DCM (20.0 V) and NMP (2.0 V) were added into RBF at room temperature under nitrogen atmosphere. The reaction mass was cooled to below 10 °C and then POCl3 (4.1 eq) was added into the reaction mass and maintained at 20-30 °C for one hour. After completion of the reaction, the temperature of the reaction mass was raised to room temperature and the pH was adjusted to ~7.0 by adding NaHCO3 aqueous solution (~50 V). The layers were separated and the aqueous layer was extracted with DCM (3×10 V). The combined organic layers were washed with saturated NaCl solution (17 V) and the organic layer was distilled off under reduced pressure to obtain the crude compound (7.0 g). The obtained crude compound was purified by silica gel column to obtain the title compound.

[0194] Yield: 3g

[0195] Step 6: Preparation of ruxolitinib phosphate

[0196]

[0197] Ruxolitinib (11.0 g, 1.0 eq.) and IPA (37 V) were added to RBF at room temperature and stirred for 30 minutes. Orthophosphoric acid solution (1.1 eq. orthophosphoric acid in 3 V of IPA) was added to the reaction mass at RT and stirred under reflux for 1 hour. The reaction mass was then cooled to room temperature and stirred at room temperature for 2 hours. The solid obtained was filtered, washed with IPA (4 V), and vacuum dried at 40-50 ° C for 6-8 hours to obtain the crude compound (11.60 g). IPA (30 V) was added to the obtained crude compound, heated to 50-60 ° C, and kept at the same temperature for 2-3 hours. The reaction mass was filtered at 30-40 ° C, washed with IPA (5 V), and dried under reduced pressure to obtain the title compound.

[0198] Yield: 8.3 g

Claims

1. A method for preparing ruxolitinib or a salt thereof, the method comprising: A) making a compound of formula 4 or a salt thereof, Reaction with a compound of formula 5, wherein 'P' represents hydrogen or an amine protecting group, and X - It is the counterbalancing anion; To provide an acid intermediate of formula 6; B) optionally, purifying the acid intermediate of Formula 6 by reacting the acid intermediate of Formula 6 with a dicyclohexylamine salt in a suitable solvent to provide a dicyclohexylamine salt of the acid intermediate of Formula 6a, and Further conversion to its free base by reacting it with a base to provide a pure acid intermediate of formula 6; C) reacting the acid intermediate of formula 6 with an alkyl chloroformate, a dialkyl dicarbonate, an alkyl or aryl sulfonyl chloride, or a sulfonic anhydride to provide a compound of formula 7a; wherein 'Y' represents COOR, SO2R, and R is selected from alkyl, aryl or aralkyl; D) reacting a compound of formula 7a with an aminating agent to provide a compound of formula 8; and E) converting the compound of formula 8 into ruxolitinib or a salt thereof.

2. The method according to claim 1, wherein the amine protecting group is selected from the group consisting of benzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-(4-trifluoromethylphenylsulfonyl)ethoxycarbonyl, tert-butoxycarbonyl, 1-adamantyloxycarbonyl, 2-adamantylcarbonyl, 2,4-dimethylpentan-3-oxycarbonyl, cyclohexyloxycarbonyl, 1,1-dimethyl-2,2,2-trichloroethoxycarbonyl, vinyl, 2-chloroethyl, 2-phenylsulfonylethyl, p-nitrobenzenesulfonyl, p-toluenesulfonyl, benzylsulfonyl, methanesulfonyl, allyl, benzyl, 2-nitrobenzyl, 4-nitrobenzyl, diphenyl-4-pyridylmethyl, N',N'-dimethylhydrazine, methoxymethyl, tert-butoxymethyl, benzyloxymethyl, 2-tetrahydropyranyl, tri(C1-4alkyl)silyl, 1,1-diethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, N-pivaloyloxymethyl.

3. The method according to claim 1, wherein the X - is a counter anion, the counter anion is selected from but not limited to Cl - Br - ,I - OMs - ,OTf - 、BF4 - PF6 - 、AsF6 - 、SbF6 - and ClO4 - of.

4. The method according to claim 1, wherein the alkyl chloroformate, dialkyl dicarbonate, alkyl or aryl sulfonyl chloride, sulfonic anhydride is selected from the group consisting of ethyl chloroformate, methyl chloroformate, isobutyl chloroformate, dimethyl dicarbonate, diethyl dicarbonate, di-tert-butyl dicarbonate, methanesulfonyl chloride, ethanesulfonyl chloride, toluenesulfonyl chloride, methanesulfonic anhydride and toluenesulfonic anhydride.

5. The method according to claim 1, wherein the aminating agent is selected from aqueous ammonia, liquid ammonia and ammonia gas.

6. A method for preparing an acid intermediate of formula 6, the method comprising: The compound of formula 4 or a salt thereof, Reaction with a compound of formula 5, wherein 'P' represents hydrogen or an amine protecting group, and X - It is the counterbalancing anion; To provide an acid intermediate of formula 6 7. A method for purifying a compound of formula 6, the method comprising: wherein 'P' represents hydrogen or an amine protecting group; reacting the compound of Formula 6 with a dicyclohexylamine salt in a suitable solvent to provide a dicyclohexylamine salt of the compound of Formula 6a, and The compound of Formula 6a can be further converted to a free base by reacting its dicyclohexylamine salt with a base to provide a pure compound of Formula 6.

8. A method for preparing ruxolitinib or a salt thereof, the method comprising: A) making an acid intermediate of formula 6, wherein 'P' represents hydrogen or an amine protecting group; reacting with an alkyl chloroformate, a dialkyl dicarbonate, an alkyl or aryl sulfonyl chloride, or a sulfonic anhydride to provide a compound of formula 7a; wherein 'Y' represents COOR, SO2R, and R is selected from alkyl, aryl or aralkyl; B) reacting a compound of formula 7a with an aminating agent to provide a compound of formula 8; and C) converting the compound of formula 8 into ruxolitinib or a salt thereof.

9. Use of the dicyclohexylamine salt of the compound represented by formula 6a or the pure compound represented by formula 6 in the preparation of ruxolitinib or its salt in, 'P' represents hydrogen or an amine protecting group.